⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 9, 2026Neurology

Establishing Primary Structure Comparability Between ABP-450 (probotulinumtoxinA) and OnabotulinumtoxinA (Botox®) to Support Biosimilarity (P11-7.010)

Chad Oh Yan Liu Kyoung Yun Kim Priscilla Too

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to establish comparability in primary structure between ABP-450 and OnabotulinumtoxinA.
Conducted comparative analysis of primary structure between ABP-450 and OnabotulinumtoxinA.
Utilized molecular techniques to evaluate structural attributes.
Confirmed comparability in primary structure, supporting the assertion of biosimilarity.
Data demonstrates alignment in structural characteristics with no significant deviations.

Implication

Demonstrates structure comparability in ABP-450 and OnabotulinumtoxinA, supporting biosimilarity.

Abstract

To demonstrate primary structure comparability between ABP-450 and the reference product (Botox®) to support biosimilarity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oh et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055cf8 https://doi.org/10.1212/wnl.0000000000216949

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Validation of the Equivalence of the Cell-Based Potency Assay Method with a Mouse LD50 Bioassay for the Potency Testing of OnabotulinumtoxinA2024 · 6 citations
2Cross-Induction of Anti-Complexing Antibodies in Patients Treated with Botulinum Toxin Formulations Containing Complexing ProteinsCohort Study · 2026
3Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference ProductOriginal Research · 2020 · 19 citations
4Real-world differences in dosing and clinical utilization of OnabotulinumtoxinA and AbobotulinumtoxinA in the treatment of upper limb spasticity2024 · 6 citations
5Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinAIn Vitro Study · 2026 · 4 citations